White House Considers Safety Review of Ibogaine
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy CMND?
A psychedelic used in some countries to treat post-traumatic stress disorder is expected to get a closer examination from the federal government on its safety and effectiveness, CBS News' Jennifer Jacobs and Celine Gounder report, citing sources. The White House is drafting an executive order that would signal the Trump administration's willingness to further U.S. research into a drug called ibogaine, the authors add. Ibogaine, a naturally occurring compound from a shrub native to Africa, is used to treat depression, anxiety, addiction, post-traumatic stress disorder and brain trauma. Clearmind Medicine (CMND), AtaiBeckley (ATAI), Cybin (HELP), Definium Therapeutics (DFTX), GH Research (GHRS), Compass Pathways (CMPS) and Psyence Biomedical (PBM) are trading higher following the news.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CMND?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CMND
About CMND
Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Clearmind Medicine's CMND-100 Trial Receives Positive DSMB Recommendation
- Clinical Trial Progress: Clearmind Medicine Inc.'s independent Data and Safety Monitoring Board has issued a positive recommendation for the ongoing FDA-approved Phase I/IIa clinical trial of CMND-100, indicating the drug's potential in treating Alcohol Use Disorder, particularly in light of limited effective treatment options.
- Positive Safety Data: Following the successful completion of the third patient cohort, top-line safety data for CMND-100 shows it was well tolerated with no serious adverse events reported, reinforcing the favorable safety profile observed in earlier cohorts.
- Dose Increase: As the trial advances to the fourth cohort, the tested dose of CMND-100 will increase to 160 mg, aimed at evaluating the drug's safety, tolerability, pharmacokinetics, and preliminary efficacy, demonstrating the company's confidence in its drug development.
- Stock Market Volatility: Despite a 28.57% drop in CMND's stock price to $0.65 during Wednesday's trading, the stock rebounded slightly to $0.66 in overnight trading, reflecting market interest and anticipation regarding the drug trial's progress.
See More
Clearmind Receives Positive Recommendation for CMND-100 Trial
- Clinical Trial Progress: Clearmind Medicine Inc. announced that its independent Data and Safety Monitoring Board (DSMB) has completed its review and recommended the continuation of the FDA-approved Phase I/IIa clinical trial of CMND-100, demonstrating positive safety data indicating good tolerability with no serious adverse events reported.
- Dose Increase: As the trial moves to the fourth cohort, the tested dose of CMND-100 will be increased to 160mg, a change aimed at further assessing its efficacy in treating Alcohol Use Disorder (AUD), which is expected to enhance the clinical trial's effectiveness and market potential.
- Multinational Study Design: This clinical trial is a multinational, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100, highlighting Clearmind's strategic positioning in addressing unmet health needs.
- Intellectual Property Strategy: Clearmind currently holds 19 patent families and 31 granted patents, with plans to seek additional patents as warranted, thereby strengthening its competitive edge in the neuroplastogen pharmaceutical sector.
See More
Clearmind's Drug Trial Achieves Primary Endpoint
- Clinical Trial Success: Clearmind Medicine Inc. announced that its CMND-100 drug has met the primary safety and tolerability endpoint in its FDA-approved Phase I/IIa clinical trial, indicating strong potential for treating Alcohol Use Disorder (AUD).
- High Safety Profile: Results from the third cohort demonstrated that CMND-100 exhibited a high safety profile even at higher dosages, with no serious adverse events reported, further confirming the drug's tolerability consistent with previous cohorts.
- Multinational Study Design: The clinical trial is a multinational, multicenter study aimed at evaluating the safety, tolerability, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD, supporting its potential as a novel non-hallucinogenic treatment option.
- Intellectual Property Strategy: Clearmind currently holds 19 patent families and 31 granted patents, with plans to seek additional patents as warranted, enhancing its competitive position in the neuroplastogen-derived therapeutics market.
See More
Clearmind Medicine Reports Positive Progress in AUD Drug Trial
- Clinical Trial Progress: Clearmind Medicine Inc. has successfully completed treatment and follow-up for 18 participants in its Phase 1/2a clinical trial for CMND-100, a non-hallucinogenic drug for Alcohol Use Disorder (AUD), reflecting strong momentum across its multinational study sites.
- Patient Recruitment Expansion: The successful treatment of four additional participants at the Tel Aviv clinical site further expands enrollment, demonstrating the operational strength of its Israeli centers while providing more data to support the drug's potential efficacy.
- Urgent Treatment Need: AUD is a chronic condition with limited existing treatments, making the development of CMND-100 significant as it may offer new therapeutic options for patients struggling with long-term recovery.
- Safety and Tolerability: CEO Dr. Adi Zuloff-Shani noted that the steady progress underscores the favorable safety and tolerability profile of CMND-100, bringing the company closer to delivering an innovative therapy for AUD and advancing its pipeline of non-hallucinogenic therapeutics.
See More
Clearmind Advances Clinical Trial for Alcohol Use Disorder
- Clinical Trial Progress: Clearmind Medicine has successfully completed treatment and follow-up for 18 participants in its FDA-approved Phase I/IIa clinical trial, indicating a favorable safety and tolerability profile for its non-hallucinogenic drug CMND-100 aimed at treating Alcohol Use Disorder, thereby enhancing the company's innovative capabilities in the biotech sector.
- Israeli Center Expansion: The successful treatment of four additional participants at the Tel Aviv clinical center demonstrates the operational strength of this site, increasing Clearmind's engagement in the multicenter study and potentially accelerating the recruitment of subsequent patients.
- Multicenter Research Advantage: Conducted at leading institutions such as Yale University, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, the trial ensures scientific rigor and enhances Clearmind's reputation within the industry, positioning it favorably for future collaborations.
- Intellectual Property Strategy: Clearmind's portfolio includes 19 patent families and 31 granted patents, with plans to seek additional patents as warranted, reflecting its long-term strategic positioning and competitive edge in the drug development landscape.
See More
Clearmind Files Patent Application in India for Next-Gen Psychedelic Compounds
- Patent Application Progress: Clearmind Medicine has filed a patent application in India for next-generation psychedelic-based compounds aimed at treating mental health disorders and addiction, further expanding its global intellectual property portfolio.
- Innovative Drug Development: The compounds protected by this patent are designed to overcome the limitations of classical psychedelics, offering potentially safer, more effective, and scalable treatment options to address underserved mental health needs.
- Intellectual Property Strategy: Clearmind currently holds 19 patent families, including 31 granted patents, and plans to seek additional patents as warranted to enhance its market competitiveness and technological barriers.
- Market Potential: By entering into an exclusive global licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, Clearmind's innovative drug development in the mental health space is poised to support its future commercialization efforts, addressing the growing market demand.
See More
Clearmind Medicine's CMND-100 Trial Receives Positive DSMB Recommendation
- Clinical Trial Progress: Clearmind Medicine Inc.'s independent Data and Safety Monitoring Board has issued a positive recommendation for the ongoing FDA-approved Phase I/IIa clinical trial of CMND-100, indicating the drug's potential in treating Alcohol Use Disorder, particularly in light of limited effective treatment options.
- Positive Safety Data: Following the successful completion of the third patient cohort, top-line safety data for CMND-100 shows it was well tolerated with no serious adverse events reported, reinforcing the favorable safety profile observed in earlier cohorts.
- Dose Increase: As the trial advances to the fourth cohort, the tested dose of CMND-100 will increase to 160 mg, aimed at evaluating the drug's safety, tolerability, pharmacokinetics, and preliminary efficacy, demonstrating the company's confidence in its drug development.
- Stock Market Volatility: Despite a 28.57% drop in CMND's stock price to $0.65 during Wednesday's trading, the stock rebounded slightly to $0.66 in overnight trading, reflecting market interest and anticipation regarding the drug trial's progress.
See More
Clearmind Receives Positive Recommendation for CMND-100 Trial
- Clinical Trial Progress: Clearmind Medicine Inc. announced that its independent Data and Safety Monitoring Board (DSMB) has completed its review and recommended the continuation of the FDA-approved Phase I/IIa clinical trial of CMND-100, demonstrating positive safety data indicating good tolerability with no serious adverse events reported.
- Dose Increase: As the trial moves to the fourth cohort, the tested dose of CMND-100 will be increased to 160mg, a change aimed at further assessing its efficacy in treating Alcohol Use Disorder (AUD), which is expected to enhance the clinical trial's effectiveness and market potential.
- Multinational Study Design: This clinical trial is a multinational, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100, highlighting Clearmind's strategic positioning in addressing unmet health needs.
- Intellectual Property Strategy: Clearmind currently holds 19 patent families and 31 granted patents, with plans to seek additional patents as warranted, thereby strengthening its competitive edge in the neuroplastogen pharmaceutical sector.
See More
Clearmind's Drug Trial Achieves Primary Endpoint
- Clinical Trial Success: Clearmind Medicine Inc. announced that its CMND-100 drug has met the primary safety and tolerability endpoint in its FDA-approved Phase I/IIa clinical trial, indicating strong potential for treating Alcohol Use Disorder (AUD).
- High Safety Profile: Results from the third cohort demonstrated that CMND-100 exhibited a high safety profile even at higher dosages, with no serious adverse events reported, further confirming the drug's tolerability consistent with previous cohorts.
- Multinational Study Design: The clinical trial is a multinational, multicenter study aimed at evaluating the safety, tolerability, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD, supporting its potential as a novel non-hallucinogenic treatment option.
- Intellectual Property Strategy: Clearmind currently holds 19 patent families and 31 granted patents, with plans to seek additional patents as warranted, enhancing its competitive position in the neuroplastogen-derived therapeutics market.
See More
Clearmind Medicine Reports Positive Progress in AUD Drug Trial
- Clinical Trial Progress: Clearmind Medicine Inc. has successfully completed treatment and follow-up for 18 participants in its Phase 1/2a clinical trial for CMND-100, a non-hallucinogenic drug for Alcohol Use Disorder (AUD), reflecting strong momentum across its multinational study sites.
- Patient Recruitment Expansion: The successful treatment of four additional participants at the Tel Aviv clinical site further expands enrollment, demonstrating the operational strength of its Israeli centers while providing more data to support the drug's potential efficacy.
- Urgent Treatment Need: AUD is a chronic condition with limited existing treatments, making the development of CMND-100 significant as it may offer new therapeutic options for patients struggling with long-term recovery.
- Safety and Tolerability: CEO Dr. Adi Zuloff-Shani noted that the steady progress underscores the favorable safety and tolerability profile of CMND-100, bringing the company closer to delivering an innovative therapy for AUD and advancing its pipeline of non-hallucinogenic therapeutics.
See More
Clearmind Advances Clinical Trial for Alcohol Use Disorder
- Clinical Trial Progress: Clearmind Medicine has successfully completed treatment and follow-up for 18 participants in its FDA-approved Phase I/IIa clinical trial, indicating a favorable safety and tolerability profile for its non-hallucinogenic drug CMND-100 aimed at treating Alcohol Use Disorder, thereby enhancing the company's innovative capabilities in the biotech sector.
- Israeli Center Expansion: The successful treatment of four additional participants at the Tel Aviv clinical center demonstrates the operational strength of this site, increasing Clearmind's engagement in the multicenter study and potentially accelerating the recruitment of subsequent patients.
- Multicenter Research Advantage: Conducted at leading institutions such as Yale University, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, the trial ensures scientific rigor and enhances Clearmind's reputation within the industry, positioning it favorably for future collaborations.
- Intellectual Property Strategy: Clearmind's portfolio includes 19 patent families and 31 granted patents, with plans to seek additional patents as warranted, reflecting its long-term strategic positioning and competitive edge in the drug development landscape.
See More
Clearmind Files Patent Application in India for Next-Gen Psychedelic Compounds
- Patent Application Progress: Clearmind Medicine has filed a patent application in India for next-generation psychedelic-based compounds aimed at treating mental health disorders and addiction, further expanding its global intellectual property portfolio.
- Innovative Drug Development: The compounds protected by this patent are designed to overcome the limitations of classical psychedelics, offering potentially safer, more effective, and scalable treatment options to address underserved mental health needs.
- Intellectual Property Strategy: Clearmind currently holds 19 patent families, including 31 granted patents, and plans to seek additional patents as warranted to enhance its market competitiveness and technological barriers.
- Market Potential: By entering into an exclusive global licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, Clearmind's innovative drug development in the mental health space is poised to support its future commercialization efforts, addressing the growing market demand.
See More
